CorpusHuman Anatomy
DigestivePhysiological process

Enterohepatic circulation of bile acids

Also known as: enterohepatic circulation, bile acid recycling, ASBT, FXR, FGF19

Bile acids secreted in bile are about 95% reabsorbed in the terminal ileum and returned to the liver in the portal blood. A pool of only about 3 g therefore recycles several times a day.

Show on body map

Overview

Bile acid pool≈3 g
Fraction reabsorbed≈95% per cycle
Cycles≈4–12 per day
Daily synthesis (= faecal loss)≈0.2–0.6 g

Hepatocytes make primary bile acids (cholic and chenodeoxycholic acid) from cholesterol, at about 0.2–0.6 g a day, enough to replace faecal loss. CYP7A1 catalyses the rate-limiting step. The bile acids are conjugated with glycine or taurine and pumped into the canaliculi by the bile salt export pump (BSEP). Between meals they are stored in the gallbladder. After a meal, CCK delivers them to the duodenum, where they emulsify fat and form micelles.

In the terminal ileum, conjugated bile salts are actively taken up by the apical sodium-dependent bile acid transporter (ASBT, IBAT). They cross the enterocyte bound to ileal bile-acid-binding protein and leave through OSTα/β. A smaller amount of deconjugated bile acid is absorbed passively in the jejunum and colon. Bile acids travel in portal blood bound to albumin. Hepatocytes extract them very efficiently at first pass through NTCP and re-secrete them. The total pool is about 3 g and cycles about 4–12 times a day, roughly twice per meal.

Feedback. Bile acids activate the nuclear receptor FXR in ileal enterocytes, which releases FGF19 into the portal blood. FGF19 acts on hepatic FGFR4 to repress CYP7A1, and hepatic FXR acting through SHP does the same. This keeps synthesis matched to the amount returned. In the colon, bacteria deconjugate and 7α-dehydroxylate bile acids into secondary bile acids (deoxycholic and lithocholic). Lithocholate is poorly reabsorbed and is detoxified by sulfation. Other substances also recirculate enterohepatically, including urobilinogen and some drugs (ethinylestradiol, mycophenolate).

Parts & subdivisions

  1. CYP7A1 (rate-limiting); conjugation; BSEP export.
  2. Bile acids are concentrated between meals.
  3. ASBT uptake and OSTα/β exit; FXR–FGF19 signalling.
  4. NTCP uptake by hepatocytes.

Function

  • Maintains a large intraluminal bile-acid supply for fat digestion from a small total pool.
  • Regulates cholesterol catabolism and bile-acid synthesis.

Clinical significance

Ileal disease or resection

With a short resection (under about 100 cm), bile acids spill into the colon and stimulate Cl⁻ and water secretion, causing bile-acid diarrhoea, which responds to bile-acid sequestrants such as colestyramine. With a longer resection the pool is depleted, causing steatorrhoea and fat-soluble vitamin deficiency. Other consequences are cholesterol gallstones (lithogenic bile) and enteric hyperoxaluria with calcium oxalate kidney stones.

Therapeutic interruption

Bile-acid sequestrants (colestyramine) bind bile acids in the gut. The liver then diverts more cholesterol into new bile-acid synthesis and upregulates LDL receptors, so plasma LDL falls. IBAT inhibitors (odevixibat, maralixibat) relieve cholestatic pruritus in PFIC and Alagille syndrome.

Compiled from standard anatomy and physiology references — see the Digestive System sources. For education only; not medical advice.